Galapagos Genomics
From Wikipedia, the free encyclopedia
Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies. Onno van de Stolpe is the CEO of the company.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Contents |
[edit] References
- Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.
[edit] See also
[edit] Source
- Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
- Een rotsvast geloof in de Vlaamse biotech
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
